Bipolar disorder and the endocannabinoid system

Bipolar disorder (formerly: manic-depressive illness) affects around 2.5 million people in Germany. The endocannabinoid system (ECS) modulates mood, sleep and impulsivity – all areas that are dysregulated in bipolar disorder. However, the relationship between cannabis and bipolar disorder is highly complex and double-edged.

Studies show that cannabis is often used by those affected as self-medication – especially in depressive phases. At the same time, THC is a recognized risk factor for triggering mania, inducing psychosis and worsening the long-term course of the disease.

Clinical study situation: findings and limitations

THC: The mania trigger

THC is the critical drug in bipolar disorder. The mechanisms are well understood:

Dopamine dysregulation: THC acutely increases mesolimbic dopamine release – the same mechanism that drives mania symptoms. In bipolar patients who are genetically predisposed to dopamine overactivity, THC can undercut the hypomanic threshold.

Sleep disruption: Manic episodes are triggered by sleep deprivation. THC suppresses deep sleep and REM, fragments the sleep architecture – a direct risk factor for mania in bipolar patients.

Mood stabilizer interaction: Lithium, valproate and lamotrigine are CYP substrates. CBD and THC influence CYP3A4 and CYP2D6 – changes in levels can lead to under- or oversupply and destabilize the therapeutic range.

CBD: potential opportunities, clear limits

In contrast to THC, CBD has a more favorable profile:

Antidepressant effect: FAAH inhibition → anandamide increase → CB1 in the limbic system; 5-HT1A agonism. Relevant for depressive phases of bipolar disorder.

Antipsychotic properties: CBD modulates dopamine signaling without direct D2 antagonization (like classic antipsychotics) – which avoids the risk of tardive dyskinesia. In individual case studies and small case series (McGuire 2018, JAMA Psychiatry), CBD showed antipsychotic effects comparable to amisulpride in schizophrenia patients.

Sleep: CBD in higher doses (150-300 mg) promotes deep sleep without REM suppression – more favorable profile than THC for mania prophylaxis.

But: There are no RCTs on CBD specifically for bipolar disorder. The evidence is based on mechanism considerations and small case series. CBD is not recommended as first-line treatment for bipolar disorder.

Who is particularly at risk?

High-risk patients for THC in bipolar disorder:
– Bipolar I with pronounced mania (higher baseline dopamine level)
– Earlier age of onset (<25 years) – correlation with poorer cannabis abuse outcome
– Family history of schizophrenia (CNR1 polymorphism carriers)
– Current mania or hypomania (absolute contraindication)
– Unstable medication levels (lithium monitoring)

Practical recommendations

Cannabis and bipolar disorder: general caution. Use should be discussed with the treating psychiatrist.

If cannabis is used: CBD-dominant preparations (lowest risk), no high-percentage THC, no use in manic/hypomanic phases, regular mood monitoring (QIDS-SR).

Medical cannabis: Possible in principle for bipolar depression with treatment resistance, but off-label and only under close psychiatric supervision. Interactions with mood stabilizers must be monitored regularly.

FAQ: Cannabis for bipolar disorder

Summary

Cannabis in bipolar disorder is a high-risk issue: THC can trigger mania and worsen the long-term course. Although CBD shows antidepressant and antipsychotic properties, there is a lack of RCT evidence specifically for bipolar disorder. Use only under psychiatric supervision, CBD-dominant, no THC in manic phases, consider the risk of psychosis. Depressive phases tend to respond better than manic phases – caution nevertheless.